Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6844—Nucleic acid amplification reactions
  • C12Q1/686—Polymerase chain reaction [PCR]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/156—Polymorphic or mutational markers
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/158—Expression markers
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/16—Primer sets for multiplex assays

Definitions

• BACKGROUND OF THE INVENTION MET is a tyrosine kinase and proto-oncogene encoded on human chromosome 7.
• the preprotein is cleaved to form alpha and beta subunits which remain associated via disulfide bonds, and act as a receptor for Hepatocyte Growth Factor.
• Activated MET induces the PI3K-AKT-mTOR pathway, involved in cell survival, and the RAS-RAF- MEK-ERK pathway, involved in cell proliferation.
• Mutations in MET are associated with a number of cancers, including renal, gastric, nervous system, sarcomas, and lung cancer. Mutations that result in higher activity or expression, or deletion of negative regulation sites are often implicated in these cancers. In particular, deletion of exon 14 and the negative regulation site at Tyr 1003 is associated with a significant percentage of non-small cell lung cancers (NSCLC) and adenocarcinomas.
• NSCLC non-small cell lung cancers
• CBL an E3 ubiquitin protein ligase
• MET is not degraded normally when the site is deleted.
• the resulting dysregulation of MET causes sustained activation of downstream cell proliferation and survival pathways.
• Detection of MET exon 14 deletion is more predictive of a positive therapeutic response to MET inhibitors than detection of gene amplification or increased mRNA or protein expression.
• a method of detecting a MET exon 14 deletion comprises: (a) obtaining a nucleic acid sample from an individual (e.g., comprising RNA, DNA, or both RNA and DNA); (b) carrying out an amplification/ detection reaction using the sample to selectively amplify and detect MET exon 13-exon 14 junction, MET exon 14-exon 15 junction, and MET exon 13-exon 15 junction; and (c) detecting the presence of a MET exon 14 deletion if the MET exon 13-exon 15 junction is detected.
• an individual e.g., comprising RNA, DNA, or both RNA and DNA
• the method further includes carrying out a reverse transcription reaction using the sample to produce cDNA before step (b).
• the reverse transcription reaction and step (b) occur in a single vessel (tube, well, microfiuidic chamber, etc.).
• step (b) comprises contacting the cDNA with (i) a primer set and probe labeled with a first label that specifically amplify and detect MET exon 13-14 junction, (ii) a primer set and probe labeled with a second label that specifically amplify and detect MET exon 14-15 junction, and (iii) a primer set and probe labeled with a third label that specifically amplify and detect MET exon 13-15 junction.
• step (c) comprises detection of the probe labeled with the third label.
• step (b) is a multiplex reaction, e.g., so that the primer sets and probes of (i), (ii), and (iii) are included in a single vessel.
• the multiplex reaction further includes an internal control, e.g., a primer set and probe labeled with a fourth label (e.g., labeled IC probe) that specifically amplify and detect an internal control.
• step (b) is carried out in separate vessels, e.g., each carrying one of the primer sets and probes of (i), (ii), and (iv), optionally multiplexed with the internal control.
• the reverse transcription and amplification/ detection reactions are carried out using quantitative reverse transcription-PCR (qRT-PCR).
• the primer set for amplifying the MET exon 13-14 junction includes a forward primer having a sequence selected from the group consisting of: SEQ ID NOs:l-8 and a reverse primer having a sequence selected from the group consisting of: SEQ ID NOs: 17-24.
• the probe for detecting the MET exon 13-14 junction has a sequence selected from the group consisting of: SEQ ID NOs: 44- 46.
• the probe for detecting the MET exon 13-14 junction has the sequence of SEQ ID NO:44.
• the probe for detecting the MET exon 13-14 junction has the sequence of SEQ ID NO:45. In some embodiments, the probe for detecting the MET exon 13-14 junction has the sequence of SEQ ID NO:46.
• the primer set for amplifying the MET exon 14-15 junction includes a forward primer having a sequence selected from the group consisting of: SEQ ID NOs:9-16 and a reverse primer having a sequence selected from the group consisting of: SEQ ID NOs: 25-38. In some embodiments, the probe for detecting the MET 14-15 junction has a sequence selected from the group consisting of: SEQ ID NOs: 47-50.
• the probe for detecting the MET 14-15 junction has the sequence of SEQ ID NO:47. In some embodiments, the probe for detecting the MET 14-15 junction has the sequence of SEQ ID NO:48. In some embodiments, the probe for detecting the MET 14-15 junction has the sequence of SEQ ID NO:49. In some embodiments, the probe for detecting the MET 14-15 junction has the sequence of SEQ ID NO:50. In some embodiments, the primer set for amplifying the MET exon 13-15 junction includes a forward primer selected from the group consisting of: SEQ ID NOs: 1-8 and a reverse primer selected from the group consisting of: SEQ ID NOs: 25- 38.
• the probe for detecting the MET exon 13-15 junction has a sequence selected from the group consisting of: SEQ ID NOs: 39-43 and 51-54. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:39. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:40. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:41. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:42. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:43.
• the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:51. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:52. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:53. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:54.
• a method of detecting a MET exon 14 deletion comprises: (a) obtaining a nucleic acid sample from an individual (e.g., comprising RNA, DNA, or both RNA and DNA); (b) carrying out an amplification/ detection reaction using the sample to selectively amplify and detect a MET exon 13-exon 15 junction; and (c) detecting the presence of a MET exon 14 deletion if the MET exon 13-exon 15 junction is detected.
• the method further includes carrying out a reverse transcription reaction using the sample to produce cDNA before step (b).
• the reverse transcription reaction and step (b) occur in a single vessel (tube, well, microfluidic chamber, etc.).
• step (b) comprises contacting the cDNA with a primer set and labeled probe (e.g., with a non-naturally occurring fluorophore or fiuorophore and quencher) that specifically amplify and detect MET exon 13-15 junction.
• the primer set comprises a forward primer complementary to a sequence in MET exon 13 and a reverse primer complementary to a sequence in MET exon 15.
• the labeled probe specifically hybridizes to the amplification product of the primer set, and includes sequence complementary to exon 13 only, exon 15 only, or from both exon 13 and 15.
• step (c) comprises detection of the labeled probe.
• the method includes in step (b), carrying out an amplification/ detection reaction using the sample to selectively amplify and detect an internal control, and in step (c), detecting the presence of the internal control if the internal control is detected.
• amplification and detection of the internal control comprises contacting the cDNA with a primer set and labeled IC probe (e.g., with a non-naturally occurring fiuorophore or fiuorophore/ quencher) that specifically amplify and detect the internal control.
• step (c) comprises detection of the labeled IC probe.
• the primer set for amplifying the MET exon 13-15 junction includes a forward primer selected from the group consisting of: SEQ ID NOs:l-8 and a reverse primer selected from the group consisting of: SEQ ID NOs: 25-38.
• the probe for detecting the MET exon 13-15 junction has a sequence selected from the group consisting of: SEQ ID NOs: 39-43 and 51-54.
• the probe for detecting the MET exon 13-15 junction has a sequence selected from the group consisting of: SEQ ID NO:43, SEQ ID NO:52, and SEQ ID NO:53.
• the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:39.
• the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:40. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:41. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:42. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:43. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:51. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:52. In some embodiments, the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:53.
• the probe for detecting the MET 13-15 junction has the sequence of SEQ ID NO:54.
• step (b) is a multiplex reaction, e.g., so that the primer sets and probes are included in a single vessel.
• the reverse transcription and amplification/ detection reactions are carried out using quantitative reverse transcription-PCR (qRT-PCR).
• the sample is enriched for RNA before reverse transcription.
• the sample is from a non-invasive source (e.g., blood, plasma, serum, urine, mucosal swab, saliva, skin, etc.).
• the sample is a biopsy, e.g., a tumor biopsy, optionally an FFPET sample.
• the individual has cancer, e.g., lung, renal, gastric, neuronal cancer, sarcoma, or
• the individual has NSCLC.
• the method further comprises providing treatment for the individual with a MET inhibitor if a MET exon 14 deletion is detected. In some embodiments, the method further comprises providing treatment for the individual with an inhibitor of a downstream effector of MET (e.g., an inhibitor of the PI3K-AKT- mTOR or RAS-RAF-MEK-ERK pathway), or with standard chemotherapy, if a MET exon 14 deletion is detected.
• a downstream effector of MET e.g., an inhibitor of the PI3K-AKT- mTOR or RAS-RAF-MEK-ERK pathway
• methods of providing a treatment for an individual comprising: (a) obtaining a nucleic acid sample from an individual (e.g., comprising RNA both RNA and DNA); (b) carrying out an amplification/ detection reaction using the sample to selectively amplify and detect MET exon 13-exon 14 junction, MET exon 14-exon 15 junction, and MET exon 13-exon 15 junction; (c) detecting the presence of a MET exon 14 deletion if the MET exon 13-exon 15 junction is detected; and (d) providing treatment for the individual with a MET inhibitor if a MET exon 14 deletion is present.
• the method further includes carrying out a reverse transcription reaction using the sample to produce cDNA before step (b).
• the reverse transcription reaction and step (b) occur in a single vessel (tube, well, microfiuidic chamber, etc.).
• step (b) comprises contacting the cDNA with (i) a primer set and probe labeled with a first label that specifically amplify and detect MET exon 13-14 junction, (ii) a primer set and probe labeled with a second label that specifically amplify and detect MET exon 14-15 junction, and (iii) a primer set and probe labeled with a third label that specifically amplify and detect MET exon 13-15 junction.
• step (c) comprises detection of the probe labeled with the third label.
• step (b) is a multiplex reaction, e.g., so that the primer sets and probes of (i), (ii), and (iii) are included in a single vessel.
• the multiplex reaction further includes an internal control, e.g., a primer set and probe labeled with a fourth label (e.g., labeled IC probe) that specifically amplify and detect an internal control.
• step (b) is carried out in separate vessels, e.g., each carrying one of the primer sets and probes of (i), (ii), and (iv), optionally multiplexed with the internal control.
• the reverse transcription and amplification/ detection reactions are carried out using quantitative reverse transcription-PCR (qRT-PCR).
• the method of providing a treatment for an individual comprises: (a) obtaining a nucleic acid sample from an individual (e.g., comprising RNA, DNA, or both RNA and DNA); (b) carrying out an amplification/ detection reaction using the sample to selectively amplify and detect MET exon 13-exon 15 junction; (c) detecting the presence of a MET exon 14 deletion if the MET exon 13-exon 15 junction is detected; and (d) providing treatment for the individual with a MET inhibitor if a MET exon 14 deletion is present.
• the method further includes carrying out a reverse transcription reaction using the sample to produce cDNA before step (b).
• step (b) comprises contacting the cDNA with a primer set and labeled probe that specifically amplify and detect MET exon 13-15 junction.
• the primer set comprises a forward primer complementary to a sequence in MET exon 13 and a reverse primer complementary to a sequence in MET exon 15.
• the labeled probe specifically hybridizes to the amplification product of the primer set, and includes sequence complementary to exon 13 only, exon 15 only, or from both exon 13 and 15.
• step (c) comprises detection of the labeled probe.
• the method includes in step (b), carrying out an amplification/ detection reaction using the sample to selectively amplify and detect an internal control, and in step (c), detecting the presence of the internal control if the internal control is detected.
• amplification and detection of the internal control comprises contacting the cDNA with a primer set and labeled IC probe (e.g., with a non-naturally occurring fiuorophore or fiuorophore and quencher) that specifically amplify and detect the internal control.
• a primer set and labeled IC probe e.g., with a non-naturally occurring fiuorophore or fiuorophore and quencher
• step (c) comprises detection of the labeled IC probe.
• step (b) is a multiplex reaction, e.g., so that the primer sets and probes are included in a single vessel.
• the reverse transcription and amplification/ detection reactions are carried out using quantitative reverse transcription-PCR (qRT-PCR).
• a method of identifying an individual with cancer comprising: (a) obtaining a sample comprising RNA from the individual; (b) carrying out a reverse transcription reaction on the RNA to produce cDNA; (c) carrying out an amplification reaction comprising contacting the cDNA with a primer set and labeled probe that specifically amplify and detect MET exon 13- 15 junction (exon 13-15 primer set and labeled exon 13-15 probe); and (d) detecting the presence of a MET exon 14 deletion if an amplification product is formed and detected by the exon 13-15 primer set and labeled exon 13-15 probe; whereby the presence of a MET exon 14 deletion mutation in the individual's sample indicates sensitivity of said individual to a MET inhibitor compound.
• the method further comprises identifying an individual indicating sensitivity to an inhibitor of a downstream effector of MET (e.g., an inhibitor of the PI3K-AKT-mTOR or RAS-RAF-MEK-ERK pathway), or with standard chemotherapy, if a MET exon 14 deletion is detected.
• a downstream effector of MET e.g., an inhibitor of the PI3K-AKT-mTOR or RAS-RAF-MEK-ERK pathway
• methods of identifying an individual with cancer comprising: (a) obtaining a nucleic acid sample from an individual (e.g., comprising RNA both RNA and DNA); (b) carrying out an amplification/ detection reaction using the sample to selectively amplify and detect MET exon 13-exon 14 junction, MET exon 14-exon 15 junction, and MET exon 13-exon 15 junction; and (c) detecting the presence of a MET exon 14 deletion if the MET exon 13-exon 15 junction is detected; whereby the presence of a MET exon 14 deletion mutation in the individual's sample indicates sensitivity of said individual to a MET inhibitor compound.
• the method further includes carrying out a reverse transcription reaction using the sample to produce cDNA before step (b).
• the reverse transcription reaction and step (b) occur in a single vessel (tube, well, microfiuidic chamber, etc.).
• step (b) comprises contacting the cDNA with (i) a primer set and probe labeled with a first label that specifically amplify and detect MET exon 13-14 junction, (ii) a primer set and probe labeled with a second label that specifically amplify and detect MET exon 14-15 junction, and (iii) a primer set and probe labeled with a third label that specifically amplify and detect MET exon 13-15 junction.
• step (c) comprises detection of the probe labeled with the third label.
• step (b) is a multiplex reaction, e.g., so that the primer sets and probes of (i), (ii), and (iii) are included in a single vessel.
• the multiplex reaction further includes an internal control, e.g., a primer set and probe labeled with a fourth label (e.g., labeled IC probe) that specifically amplify and detect an internal control.
• step (b) is carried out in separate vessels, e.g., each carrying one of the primer sets and probes of (i), (ii), and (iv), optionally multiplexed with the internal control.
• the reverse transcription and amplification/ detection reactions are carried out using quantitative reverse transcription-PCR (qRT-PCR).
• the method of identifying an individual with cancer comprises: (a) obtaining a nucleic acid sample from an individual (e.g., comprising RNA, DNA, or both RNA and DNA); (b) carrying out an amplification/ detection reaction using the sample to selectively amplify and detect MET exon 13-exon 15 junction; and (c) detecting the presence of a MET exon 14 deletion if the MET exon 13-exon 15 junction is detected; whereby the presence of a MET exon 14 deletion mutation in the individual's sample indicates sensitivity of said individual to a MET inhibitor compound.
• the method further includes carrying out a reverse transcription reaction using the sample to produce cDNA before step (b).
• the reverse transcription reaction and step (b) occur in a single vessel (tube, well, microfluidic chamber, etc.).
• step (b) comprises contacting the cDNA with a primer set and labeled probe that specifically amplify and detect MET exon 13-15 junction.
• the primer set comprises a forward primer complementary to a sequence in MET exon 13 and a reverse primer complementary to a sequence in MET exon 15.
• the labeled probe specifically hybridizes to the amplification product of the primer set, and includes sequence complementary to exon 13 only, exon 15 only, or from both exon 13 and 15.
• step (c) comprises detection of the labeled probe.
• the method includes in step (b), carrying out an amplification/ detection reaction using the sample to selectively amplify and detect an internal control, and in step (c), detecting the presence of the internal control if the internal control is detected.
• amplification and detection of the internal control comprises contacting the cDNA with a primer set and labeled IC probe (e.g., with a non-naturally occurring fiuorophore or fiuorophore and quencher) that specifically amplify and detect the internal control.
• step (c) comprises detection of the labeled IC probe.
• step (b) is a multiplex reaction, e.g., so that the primer sets and probes are included in a single vessel.
• the reverse transcription and amplification/ detection reactions are carried out using quantitative reverse transcription-PCR (qRT-PCR).
• the method further comprises providing treatment for the individual with an inhibitor of a downstream effector of MET (e.g., an inhibitor of the PI3K-AKT-mTOR or RAS-RAF-MEK-ERK pathway), or with standard chemotherapy, if a MET exon 14 deletion is detected.
• an inhibitor of a downstream effector of MET e.g., an inhibitor of the PI3K-AKT-mTOR or RAS-RAF-MEK-ERK pathway
• the sample is enriched for RNA before reverse transcription.
• the sample is from a non-invasive source (e.g., blood, plasma, serum, urine, mucosal swab, saliva, skin, etc.).
• the sample is a biopsy, e.g., a tumor biopsy, optionally an FFPET sample.
• the individual has cancer, e.g., lung, renal, gastric, neuronal cancer, sarcoma, or
• the individual has NSCLC.
• the method further comprises identifying an individual with cancer, wherein, if a MET exon 14 deletion is detected in the individual's sample, the individual's sample indicates sensitivity of said individual to an inhibitor of a downstream effector of MET (e.g., an inhibitor of the PI3K-AKT-mTOR or RAS-RAF- MEK-ERK pathway), or with standard chemotherapy.
• a downstream effector of MET e.g., an inhibitor of the PI3K-AKT-mTOR or RAS-RAF- MEK-ERK pathway
• kits for detecting MET exon 14 deletion in a nucleic acid sample.
• the kit comprises (a) a primer set and a probe labeled with a first label that specifically amplify and detect MET exon 13-14 junction; (b) a primer set and a probe labeled with a second label that specifically amplify and detect MET exon 14-15 junction; and a primer set and a probe labeled with a third label that specifically amplify and detect MET exon 13- 15 junction.
• the sequences of the primers and probes are set forth as described above herein.
• the kit further comprises (d) a primer set and probe labeled with a fourth label that specifically amplify and detect an internal control.
• the first, second, and third labels are the same (e.g., for detection in separate vessels).
• the first and second labels are the same, but different than the third label.
• the first, second, and third labels are different (e.g., for a multiplex reaction).
• the kit comprises a primer set and a labeled probe (e.g., non- naturally labeled probe, e.g., with a fiuorophore or fiuorophore/ quencher) that specifically amplify and detect MET exon 13- 15 junction.
• a labeled probe e.g., non- naturally labeled probe, e.g., with a fiuorophore or fiuorophore/ quencher
• the primer set comprises a forward primer complementary to a sequence in MET exon 13 and a reverse primer complementary to a sequence in MET exon 15.
• the labeled probe specifically hybridizes to the amplification product of the primer set, and includes sequence complementary to exon 13 only, exon 15 only, or from both exon 13 and 15.
• the sequences of the primers and probe are set forth as described above.
• the kit further comprises (d) a primer set and labeled probe that specifically amplify and detect an internal control (e.g., labeled IC probe, distinctly labeled from the labeled probe specific for the MET exon 13-15 junction amplification product).
• the kit further includes a reverse transcriptase enzyme and a thermostable DNA polymerase, or an enzyme that has both activities.
• the kit further comprises buffer (e.g., buffer that facilitates amplification) and/or dNTPs.
• the kit further comprises a positive control comprising nucleic acids encoding MET exon 14 deletion.
• the kit further comprises a negative control comprising nucleic acids that do not encode MET exon 14 deletion.
• the kit further comprises components for purification (enrichment) of RNA from a sample from an individual. BRIEF DESCRIPTION OF THE DRAWINGS
• Figure 1 depicts the alpha and beta subunits of mature MET, and shows the position of the ubiquination site at Y1003.
• CBL binds to Y1003 when it is phosphorylated
• Y1003 is not present in exon 14 deleted MET.
• Figure 2 shows an exemplary assay design for detection of MET exon 14 deletion.
• the mutant form is detected using a FAM-labeled probe specific for the exon 13-exon 15 junction, while the wild type forms are detected using a HEX-labeled probe specific for the exon 13-exon 14 junction and a JA270-labeled probe specific for the exon 14- exonl5 junction.
• An internal control is detected with a Cy5.5-labeled probe, e.g., to standardize for nucleic acid concentration and quality.
• Figure 3 provides further information about the exemplary assay design. Exons 13, 14, and 15 of wild type MET transcript are shown on top of the top panel. Primers are represented by arrows, and amplicons produced by the primers are shown just below hybridized to specific, labeled probes. The bottom panel shows exons 13 and 15 joined, exemplary primer positions, and the resulting amplicon hybridized to specific labeled probe.
• Figure 4 shows the result of the multiplex reaction depicted in Figures 2 and 3 for the mutant form (FAM channel).
• the x-axis shows copy number of the mutant sequence and the y-axis shows Ct.
• the figure shows that Ct decreases with increasing copy number in a linear fashion, and that the assay is sensitive enough to detect 30 copies.
• Figure 5 shows the result of the multiplex reaction for the wild type form exon 13-exon 14 junction (HEX channel). As with the mutant reaction, Ct is inversely related to wild type copy number, the reaction is linear, and sensitive enough to detect 30 copies.
• Figure 6 shows the result of the multiplex for the wild type form exon 14-exon 15 junction (JA270 channel). Again, the data show that Ct is inversely related to wild type copy number, the reaction is linear, and sensitive enough to detect 30 copies.
• Figure 7 shows that detection of the exon 13-exon 15 junction is specific.
• the x axis shows cycle number and the y axis shows FAM signal.
• Mut 1 and Mut2 are samples from MET exon 14 deleted cell lines. Wild type samples from WT1, WT2, and UHR (universal human RNA) do not generate a signal.
• Figure 8 shows the sensitivity of detection of the exon 13-exon 15 junction. Ct increases by about 2 between 100 copies and 30 copies mutant cell line RNA in wild type plasma, while a larger Ct increase is seen with only 10 copies mutant cell line RNA.
• the right panel shows the result of the internal control, which indicates roughly equal input between the samples.
• Figure 9 shows an exemplary assay design.
• the top transcript represents unspliced wild type MET and the bottom transcript represents MET with exon 14 spliced out.
• the primer set (arrows) includes a first (forward) primer positioned in exon 13 and a second (reverse) primer positioned in exon 15 so that an amplification product is formed when exon 14 is spliced out.
• the probe is designed to specifically bind the amplification product, be it a sequence in exon 13 only, exon 15 only, or spanning an exon 13-exon 15 junction (as shown).
• Figure 10 shows the specificity of the assay design depicted in Figure 9.
• the probe specific for the exon 13- exon 15 amplification product is labeled with FAM(left graph), while a probe specific for an internal control RNA is labeled with CY5.5 (right graph).
• qRT-PCR is shown for RNA from 2 cell lines with exon 14 spliced out (noted in left graph), 2 wild type cell lines, and UHR (Universal Human RNA).
• Figure 11 shows Limit of Detection (LOD) and Linearity data using the amount of MET exon 14 spliced transcript indicated on the x-axis spiked into 0.1 ng/ reaction UHR. The splice product is detectable in the linear range down to 10 copies.
• Figure 12 shows LOD and Linearity using MET exon 14 spliced transcript from 2 different cell lines in the amount indicated on the x-axis spiked into 50 ng RNA from FFPET (formaldehye fixed paraffin embedded tissue).
• the splice product is detectable in the linear range down to 10 copies.
• Figure 13 shows LOD and Linearity data using MET exon 14 spliced transcript from 2 different cell lines in the amount indicated on the x-axis spiked into RNA from healthy donor plasma cfRNA. Again, the LOD is about 10 copies in the linear range.
• a multiplex reaction can include more than one primer set and more than one probe, specific for different portions or variants of a gene or transcript, or specific for different genes or transcripts.
• the terms "receptacle,” “vessel,” “tube,” “well,” “chamber,” “microchamber,” etc. refer to a container that can hold reagents or an assay. If the receptacle is in a kit and holds reagents, or is being used for an amplification reaction, it can be closed or sealed to avoid contamination or evaporation. If the receptacle is being used for an assay, it can be open or accessible, at least during set up of the assay.
• MET exon 14 deletion refers to a MET gene that is chromosomally rearranged or mutated, or a MET transcript that is spliced to remove at least a portion of exon 14 of MET, i.e., the portion encoding negative regulation site Tyr 1003 in the juxtamembrane region of the MET protein.
• Various mutations at the DNA level can result in exon 14 skipping (see, e.g., Kong- Beltran et al. (2006) Cancer Res. 66; Dhanasekharan et al. (2014) Nature
• the presently described assays detect deletion of the entire exon 14 of MET, which encodes 47 amino acids.
• obtaining a sample from an individual means that a biological sample from the individual is provided for testing.
• the obtaining can be directly from the individual, or from a third party that directly obtained the sample from the individual.
• providing treatment for an individual means that the treatment is actually administered to the individual (e.g., an in-patient injection), or that it is made available to the individual, so that the individual or third party actually administers the treatment.
• the term "formed and detected,” in reference to an amplification product, indicates that the amplification product is formed and detected at a level that is higher than a base-line negative level.
• the base-line can be based on a negative control, e.g., set at the level of signal generated by a wild type sample in the case of amplifying and detecting a mutant sequence.
• the base-line can also be set slightly above the signal of the negative control (e.g., 1-5%) to allow for some variation in assay performance while avoiding false positive results for the mutant sequence.
• a negative control e.g., set at the level of signal generated by a wild type sample in the case of amplifying and detecting a mutant sequence.
• the base-line can also be set slightly above the signal of the negative control (e.g., 1-5%) to allow for some variation in assay performance while avoiding false positive results for the mutant sequence.
• nucleic acid refers to polymers of nucleotides (e.g., ribonucleotides or deoxyribo-nucleotides) and includes naturally- occurring (adenosine, guanidine, cytosine, uracil and thymidine), non-naturally occurring, and modified nucleic acids.
• the term is not limited by length (e.g., number of monomers) of the polymer.
• a nucleic acid may be single-stranded or double- stranded and will generally contain 5'-3' phosphodiester bonds, although in some cases, nucleotide analogs may have other linkages.
• nucleotides Monomers are typically referred to as nucleotides.
• non-natural nucleotide or “modified nucleotide” refers to a nucleotide that contains a modified nitrogenous base, sugar or phosphate group, or that incorporates a non-natural moiety in its structure.
• non-natural nucleotides include dideoxynucleotides, biotinylated, aminated, deaminated, alkylated, benzylated and fiuorophore-labeled nucleotides.
• primer refers to a short nucleic acid (an oligonucleotide) that acts as a point of initiation of polynucleotide strand synthesis by a nucleic acid polymerase under suitable conditions.
• Polynucleotide synthesis and amplification reactions typically include an appropriate buffer, dNTPs and/or rNTPs, and one or more optional cofactors, and are carried out at a suitable temperature.
• a primer typically includes at least one target-hybridized region that is at least substantially complementary to the target sequence (e.g., having 0, 1, 2, or 3 mismatches). This region of is typically about 8 to about 40 nucleotides in length, e.g., 12-25 nucleotides.
• a “primer set” refers to a forward and reverse primer that are oriented in opposite directions relative to the target sequence, and that produce an amplification product in amplification conditions.
• the primer set can further include and additional forward or reverse primer, e.g., to carry out allele-specific amplification.
• a primer set can also share a forward or reverse primer with another primer set, e.g., a common forward or reverse primer.
• the terms forward primer and reverse primer are arbitrarily assigned and do not indicate orientation in relation to coding sequence, etc., unless otherwise noted.
• probe means any molecule that is capable of selectively binding to a specifically intended target biomolecule, for example, a nucleic acid sequence of interest that hybridizes to the probes.
• the probe is detectably labeled with at least one non- nucleotide moiety (i.e., non-naturally occurring moiety).
• the probe is labeled with a fiuorophore and quencher.
• the term “specifically amplifies” indicates that a primer set amplifies a target sequence more than non-target sequence at a statistically significant level.
• the term “specifically detects” indicates that a probe will detect a target sequence more than non-target sequence at a statistically significant level.
• specific amplification and detection can be determined using a negative control, e.g., a sample that includes the same nucleic acids as the test sample, but not the target sequence.
• primers and probes that specifically amplify and detect a target sequence result in a Ct that is readily distinguishable from background (non-target sequence), e.g., a Ct that is at least 2, 3, 4, 5, 5-10, 10-20, or 10-30 cycles less than background.
• complementarity refers to the ability of a nucleic acid in a polynucleotide to form a base pair with another nucleic acid in a second
• the sequence A-G-T (A-G-U for RNA) is complementary to the sequence T-C-A (U-C-A for RNA).
• Complementarity may be partial, in which only some of the nucleic acids match according to base pairing, or complete, where all the nucleic acids match according to base pairing.
• a probe or primer is considered "specific for" a target sequence if it is at least partially complementary to the target sequence.
• the degree of complementarity to the target sequence is typically higher for a shorter nucleic acid such as a primer (e.g., greater than 80%, 90%, 95%, or higher) than for a longer sequence.
• nucleic acids in the context of two or more nucleic acids, or two or more polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides, or amino acids, that are the same (e.g., about 60% identity, e.g., at least any of 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters, or by manual alignment and visual inspection.
• Percent identity is typically determined over optimally aligned sequences, so that the definition applies to sequences that have deletions and/or additions, as well as those that have substitutions.
• the algorithms commonly used in the art account for gaps and the like.
• identity exists over a region comprising an a sequence that is at least about 8-25 amino acids or nucleotides in length, or over a region that is 50-100 amino acids or nucleotides in length, or over the entire length of the reference sequence.
• kit refers to any manufacture (e.g., a package or a container) including at least one reagent, such as a nucleic acid probe or probe pool or the like, for specifically amplifying, capturing, tagging/converting or detecting RNA or DNA as described herein.
• manufacture e.g., a package or a container
• reagent such as a nucleic acid probe or probe pool or the like
• amplification conditions refers to conditions in a nucleic acid amplification reaction (e.g., PCR amplification) that allow for hybridization and template-dependent extension of the primers.
• amplicon or “amplification product” refers to a nucleic acid molecule that contains all or a fragment of the target nucleic acid sequence and that is formed as the product of in vitro amplification by any suitable amplification method.
• a forward and reverse primer defines the borders of an amplification product.
• telomere sequence when applied to primers, indicates that the primers, under appropriate conditions (e.g., in the presence of a nucleotide polymerase and NTPs), will produce the defined amplification product.
• appropriate conditions e.g., in the presence of a nucleotide polymerase and NTPs
• PCR Protocols A Guide to Methods and Applications (Innis et al, Academic Press, NY, 1990)
• amplification product refers to the product of an amplification reaction.
• the amplification product includes the primers used to initiate each round of polynucleotide synthesis.
• An "amplicon” is the sequence targeted for amplification, and the term can also be used to refer to amplification product.
• the 5' and 3' borders of the amplicon are defined by the forward and reverse primers.
• sample refers to any composition containing or presumed to contain nucleic acid.
• the term includes purified or separated components of cells, tissues, or blood, e.g., DNA, RNA, proteins, cell-free portions, or cell lysates.
• the sample is typically FFPET, e.g., from a tumor or metastatic lesion.
• the sample can also be from frozen or fresh tissue, or from a liquid sample, e.g., blood or a blood component (plasma or serum), urine, semen, saliva, sputum, mucus, semen, tear, lymph, cerebral spinal fluid, mouth/throat rinse, bronchial alveolar lavage, material washed from a swab, etc.
• Samples also may include constituents and components of in vitro cultures of cells obtained from an individual, including cell lines.
• the sample can also be partially processed from a sample directly obtained from an individual, e.g., cell lysate or blood depleted of red blood cells.
• a "control" sample or value refers to a value that serves as a reference, usually a known reference, for comparison to a test sample or test conditions.
• a test sample can be taken from a test condition, e.g., from an individual suspected of having cancer, and compared to samples from known conditions, e.g., from a cancer-free individual (negative control), or from an individual known to have cancer (positive control).
• a control can also represent an average value or a range gathered from a number of tests or results.
• a control can also be prepared for reaction conditions.
• a control for the presence, quality, and/ or quantity of nucleic acid can include primers or probes that will detect a sequence known to be present in the sample (e.g., a housekeeping gene such as beta actin, beta globin, glyceraldehyde 3- phosphate dehydrogenase (GAPDH), ribosomal protein L37 and L38, PPIase, EIF3, eukaryotic translation elongation factor 2 (eEF2), DHFR, or succinate dehydrogenase)
• a housekeeping gene such as beta actin, beta globin, glyceraldehyde 3- phosphate dehydrogenase (GAPDH), ribosomal protein L37 and L38, PPIase, EIF3, eukaryotic translation elongation factor 2 (eEF2), DHFR, or succinate dehydrogenase
• a known added polynucleotide e.g., having a designated length and/
• a negative control is one free of nucleic acids, or one including primers or probes specific for a sequence that would not be present in the sample, e.g., from a different species.
• controls can be designed for assessment of any number of parameters. For example, a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life) or therapeutic measures (e.g., comparison of benefit and/or side effects). Controls can be designed for in vitro applications.
• Controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant.
• label refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
• useful labels include fluorescent dyes, luminescent agents, radioisotopes (e.g., 32 P, 3 H), electron-dense reagents, or an affinity- based moiety, e.g., a poly-A (interacts with poly-T) or poly-T tag (interacts with poly- A), a His tag (interacts with Ni), or a strepavidin tag (separable with biotin).
• a biomolecule DNA, RNA, protein, etc. attached to a label, tag, or detectable moiety is not a composition that occurs in nature
• Samples for nucleic acid amplification can be obtained from any source suspected of containing nucleic acid.
• the sample is from a human source.
• the sample is obtained in a non-invasive manner, e.g., blood or a blood fraction, urine, skin, swab, or saliva.
• Samples can also be taken from formalin fixed paraffin embedded tissue (FFPET), tissue biopsy, brochoalveolar lavage, or cultured cells (e.g., obtained from a patient, or representing a control).
• the sample is taken from lung tissue or a cell population that includes lung cells, e.g., lung cancer cells.
• the cells can be separated out (e.g., using size-based filtration or centrifugation), thereby leaving cell free nucleic acids (cfNA), including nucleic acids in exosomes, microvesicles, viral particles, or those circulating freely.
• the cells can be lysed to obtain cellular nucleic acids, either in the presence of magnetic glass particles (MGPs) or before addition of the cellular lysate to the MGPs.
• the nucleic acids DNA, RNA, or both
• are isolated from other components of the sample e.g., proteins, membranes, lipids, etc., before amplification and/or detection.
• purified nucleic acids do not indicate that the nucleic acids are 100% free of other substances, but that the nucleic acids are substantially enriched compared to the original sample.
• purified nucleic acids can be 2-, 3-, 4-, 5-, 10-, 20-, 50-, 100-fold enriched compared to the original sample, or more.
• purified nucleic acids are in aqueous solution having less than 20%, 10%, 5%, 2%, 1%, 0.5% or 0.1% non-nucleic acid residual from the sample.
• the presently described assays rely on mRNA encoding MET.
• transcripts from any cell type expressing MET e.g., epithelial cells.
• Samples can be taken from any cell or cell-free source suspected of carrying tumor nucleic acids (e.g., cancer biopsy or circulating nucleic acids).
• RNA is collected, though in some embodiments, the test can be used on previously prepared cDNA.
• the nucleic acid sample (isolated or not) can be used for detection and quantification, e.g., using nucleic acid amplification, e.g., using any primer-dependent method.
• a preliminary reverse transcription step is carried out (also referred to as RT-PCR, not to be confused with real time PCR). See, e.g., Hierro et al. (2006) 72:7148.
• qRT-PCR refers to reverse transcription followed by quantitative PCR. Both reactions can be carried out in a single tube without
• a polyT primer can be used to reverse transcribe all mRNAs in a sample with a polyA tail, random oligonucleotides can be used, or a primer can be designed that is specific for a particular target transcript that will be reverse transcribed into cDNA.
• the cDNA can form the initial template strand to be for quantitative amplification (real time or quantitative PCR, i.e., RTPCR or qPCR).
• qPCR allows for reliable detection and measurement of products generated during each cycle of PCR process.
• kits and reagents are commercially available, e.g., from Roche Molecular Systems, Life Technologies, Bio-Rad, etc. See, e.g., Pfaffi, Methods: The ongoing evolution of qPCR vol. 50(4), (2010), p. 215-216.
• a separate reverse transcriptase and thermostable DNA polymerase can be used, e.g., in a two-step (reverse transcription followed by addition of DNA polymerase and amplification) or combined reaction (with both enzymes added at once).
• the target nucleic acid is amplified with a thermostable polymerase with both reverse transcriptase activity and DNA template-dependent activity.
• Exemplary enzymes include Tth DNA polymerase, the C. therm Polymerase system, and those disclosed in US20140170730 and US20140051126.
• Taq or a Taq derivative is used for amplification (e.g., Z05, C21, etc.).
• the reverse transcriptase is from MMLV, AMV, or is a derivative thereof.
• Probes for use as described herein can be labeled with a fiuorophore and quencher (e.g., TaqMan, LightCycler, Molecular Beacon, Scorpion, or Dual Labeled probes).
• a fiuorophore and quencher e.g., TaqMan, LightCycler, Molecular Beacon, Scorpion, or Dual Labeled probes.
• fluorophores include FAM, JOE, JA270, TET, Cal Fluor Gold 540, HEX, VIC, Cal Fluor Orang 560, TAMRA, Cyanine 3, Quasar 570, Cal Fluor Red 590, Rox, Texas Red, Cyanine 5, Quasar 670, and Cyanine 5.5.
• Appropriate quenchers include TAMRA (for FAM, JOE, and TET), DABCYL, and BHQ1-3.
• Detection devices are known in the art and can be selected as appropriate for the selected labels. Detection devices appropriate for quantitative PCR include the cobas * and Light Cycler * systems (Roche), PRISM 7000 and 7300 real-time PCR systems (Applied Biosystems), etc. Six-channel detection is available on the CFX96 Real Time PCR Detection System (Bio-Rad) and Rotorgene Q (Qiagen), allowing for a higher degree of multiplexing.
• Results can be expressed in terms of a threshold cycle (abbreviated as Ct, and in some instances Cq or Cp).
• Ct a threshold cycle
• a lower Ct value reflects the rapid achievement of a predetermined threshold level, e.g., because of higher target nucleic acid concentration or a more efficient amplification.
• a higher Ct value may reflect lower target nucleic acid concentration, or inefficient or inhibited amplification.
• the threshold cycle is generally selected to be in the linear range of amplification for a given target. In some
• the Ct is set as the cycle at which the growth signal exceeds a pre-defined threshold line, e.g., in relation to the baseline, or by determining the maximum of the second derivation of the growth curve. Determination of Ct is known in the art, and described, e.g., in US Patent No. 7363168.
• kits Provided herein are kits for multiplex qRT-PCR assays to detect MET exon 14 deletions in a sample.
• the kit includes primers and probes for
• transcripts encoding MET exon 13- exon 14, exon 14-exon 15, and exon 13-exon 15 junctions.
• junction-specific primer sets and probes can be mixed and matched in any combination.
• each of the three junctions can be detected in a single vessel, along with an internal control.
• the assay can be carried out with a lower degree of multiplexing, or in non-multiplex fashion.
• each junction can be individually detected in a separate vessel, e.g., with an internal control.
• the kit includes primers and a probe for amplification, detection and/ or quantification of transcripts encoding MET exon 13-exon 15 junctions.
• primers e.g., RT primer, and forward and reverse primers that specifically amplify a MET exon 13-exon 15 junction amplification product
• probe specific for the MET exon 13-exon 15 junction amplification product
• primers and a probe can be mixed with primers and a probe that specifically amplify and detect an internal control, or provided in a separate vessel.
• the mixtures further comprise buffers, dNTPs, and other elements (e.g., cofactors or aptamers) appropriate for reverse transcription and amplification.
• the mixture is concentrated, so that an aliquot is added to the final reaction volume, along with sample (e.g., RNA), enzymes, and/ or water.
• the kit further comprises reverse transcriptase (or an enzyme with reverse transcriptase activity), and/or DNA polymerase (e.g., thermostable DNA polymerase such as Taq, Z05, and derivatives thereof).
• the kit further includes components for RNA purification from a sample, e.g., a plasma or FFPET sample.
• a sample e.g., a plasma or FFPET sample.
• the kit can include components from the cobas * 6800/8800 Sample Prep Kits, High Pure or MagNA Pure RNA Isolation Kits (Roche), miRNeasy or RNeasy FFPE Kits (Qiagen), PureLink FFPE RNA Isolation Kit (Thermo Fisher), ThruPLEX Plasma-seq (Beckman Coulter), etc.
• the kit further includes at least one control sample, e.g., nucleic acids from non-cancer sample (or pooled samples), or from a known MET exon 14 deleted sample (or pooled samples).
• the kit further includes consumables, e.g., plates or tubes for nucleic acid preparation, tubes for sample collection, etc.
• the kit further includes instructions for use, reference to a website, or software.
• MET mutations are associated with a number of different cancers, including renal, gastric, and those of the central nervous system, as well as sarcomas.
• MET exon 14 deletion in particular is associated with non-small cell lung cancer (NSCLC) and lung adenocarcinomas, found in 2% and 4% of these cancers, respectively.
• NSCLC non-small cell lung cancer
• NCCN National Comprehensive Cancer Network
• MET inhibitors crizotinib also inhibits ALK and ROSl
• cabozantinib also inhibits VEGFR2 and RET
• Additional small molecule MET inhibitors are being tested, including INCB28060 (Incyte), AMG-458 (Amgen), PF-04217903 (Pfizer), PF- 02341066 (Pfizer), E7050 (Eisai), MK-2461 (Merck), BMS-777607 (BMS), JNJ- 38877605 (Johnson & Johnson), ARQ197 (ArQule), GSK/1363089/XL880 (GSK/ Exelexis), and XL184 (BMS/ Exelexis).
• Additional MET inhibitors include biologies, e.g., antibodies or antibody fragments specific for MET (e.g., activated MET).
• Patients having a MET exon 14 deletion can also benefit from standard chemotherapy.
• This can include CHOP (cyclophosphamide; doxorubicin; vincristine; and
• prednisolone or R-CHOP, which further includes rituximab and/or etoposide.
• the cocktail can be administered periodically for a set period of time, or until reduction in tumor size and/or symptoms are detected.
• the CHOP or R-CHOP can be administered every 2 or 3 weeks. Treatment typically begins with a low dose so that side effects can be determined, and the dose increased until side effects appear or within the patient's tolerance. VII. Examples
• Primers were designed to amplify across the junction of exon 13-exon 15 (mutant or exon 14 deleted) and exon 13-exon 14 and exon 14-exon 15 (wild type). Probes specific for the junction point of each amplicon were also prepared, and labeled with different labels for multiplex amplification and detection. Primers and a probe were also designed for an internal control, in this case SDH (succinyl dehydrogenase).
• MET13-FWD refers to a forward primer in MET exon 13
• MET14-FWD refers to a forward primer in MET exon 14
• MET14-REV refers to a reverse primer in MET exon 14
• MET15-REV refers to a reverse primer in MET exon 15
• MET13-15-PRB refers to a probe that hybridizes with nucleotides at the junction of MET exons 13 and 15
• MET13-14-PRB refers to a probe that hybridizes with nucleotides at the junction of MET exons 13-14
• MET 14-15-PRB refers to a probe that hybridizes with nucleotides at the junction of MET exons 14-15.
• MET14-FWD5 13 AATGGTTTCAAATGAATCTGTAGACT
• AGTTTCCTAATTCAT pdU C-5 propynyl-dU (non-natural substitute for T)
• pdC C-5 propynyl-dC (non-natural substitute for C)
• Me dC 5-methyl-2'-dC (non-natural substitute for C)
• G clamp AP-dC (non-natural substitute for C)
• N6 Bz dA N6-benzoyl-2'-deoxyadenosine (non-natural substitute for A)
• FAM, HEX, JA270 fluorophores
• a multiplex assay was run with MET 13 FWD, MET 14 FWD, MET 14 REV, and MET 15 REV primers, and one each of the differently labeled MET13-14-PRB, MET13-15- PRB, and MET14-15-PRB probes. Internal control primer and Cy5.5-labeled probe were also included.
• Results are shown in Figures 4-6.
• Figure 4 shows signal of MET exon 14 deleted sample vs copy number of exon 14 deleted RNA.
• Figures 5 and 6 show signal of wild type MET (exon 13-exon 14 and exon 14-exon 15, respectively) vs copy number of wild type RNA. Each of the graphs show that the assay is sensitive enough to detect 30 copies of target RNA input.
• Figure 7 shows that the assay is also specific. Signal for exon 13-exon 15 junction (FAM) is shown for mutant cell lines (Mut 1 and Mut 2), wild type cell lines (WTl and WT2), and universal human RNA (UHR). As shown in Figure 7, no signal was detected for samples lacking the MET exon 14 deletion.
• FAM exon 13-exon 15 junction
• UHR universal human RNA
• exon 13-exon 14 and exon 14-exon 15 amplification products are almost always produced regardless of whether the sample is MET wild type or has a MET exon 14 deletion.
• a different assay format was designed to focus on amplification and detection of the exon 13-exon 15 junction. In this case, only one MET amplification reaction is carried out, with a forward primer complementary to a sequence in exon 13 and a reverse primer complementary to a sequence in the opposite orientation in exon 15.
• the resulting amplification product has sequence from exon 13 and sequence from exon 15, and can be detected with a probe specific for any portion of the amplification product.
• the probe can be specific for exon 13 sequence only, exon 15 sequence only, or junction of the exon sequences.
• MET splicing is heterogeneous, and thus multiple variant amplification products can be produced.
• the probe can be designed to capture multiple exon 14 splice variants, or multiple probes can be designed to capture different exon 14 splice variants.
• Suitable MET13-FWD and MET 15 -REV primers, and MET13-15-PRB probes are shown in Table 1 above.
• An exception is the MET13-15-PRB9 antisense orientation probe that does not hybridize to MET exon 13-exon 15 amplification products, and that can be used for a control.
• Figure 10 shows the specificity of the assay design depicted in Figure 9. The probe specific for the exon 13- exon 15 amplification product is labeled with FAM (left graph), while a probe specific for an internal control RNA is labeled with CY5.5 (right graph).
• qRT-PCR is shown for RNA from 2 cell lines with exon 14 spliced out (noted in left graph), 2 wild type cell lines, and UHR (Universal Human RNA). Only the exon 14 spliced samples show signal.
• Figure 11 shows Limit of Detection (LOD) and Linearity data using the amount of MET exon 14 spliced transcript indicated on the x-axis spiked into 0.1 ng/ reaction UHR. The exon 14 spliced transcript is detectable in the linear range down to 10 copies. Internal control is indicated with squares and exon 14 spliced transcript is indicated with diamonds.
• Figure 12 shows LOD and Linearity using MET exon 14 spliced transcript from 2 different cell lines in the amount indicated on the x-axis spiked into 50 ng RNA from FFPET (formaldehye fixed paraffin embedded tissue).
• the exon 14 spliced transcript is detectable in the linear range down to 10 copies.
• the exon 14 spliced cell line transcripts from cell lines are shown in squares and diamonds (along the line) with the internal controls in squares and triangles, respectively.
• Figure 13 shows LOD and Linearity data using MET exon 14 spliced transcript from 2 different cell lines in the amount indicated on the x-axis spiked into RNA from healthy donor plasma cfRNA. Again, the LOD is about 10 copies in the linear range.
• the exon 14 spliced cell line transcripts from cell lines are shown in squares and diamonds (along the line) with the internal controls in squares and triangles, respectively.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Engineering & Computer Science (AREA)
• Analytical Chemistry (AREA)
• Genetics & Genomics (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pathology (AREA)
• Hospice & Palliative Care (AREA)
• Oncology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=58800788

Family Applications (1)

Country Status (7)

Cited By (7)

Families Citing this family (5)

Family Cites Families (4)

• 2017
  • 2017-05-11 CA CA3023839A patent/CA3023839A1/en active Pending
  • 2017-05-11 JP JP2018559197A patent/JP7389551B2/ja active Active
  • 2017-05-11 ES ES17726561T patent/ES2978995T3/es active Active
  • 2017-05-11 EP EP17726561.8A patent/EP3455375B1/en active Active
  • 2017-05-11 WO PCT/EP2017/061310 patent/WO2017194668A1/en not_active Ceased
  • 2017-05-11 US US15/592,475 patent/US11913072B2/en active Active
  • 2017-05-11 CN CN201780029236.XA patent/CN109072293A/zh active Pending

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events